BioCardia has completed clinical consultations with Japan's Pharmaceuticals and Medical Devices Agency for the CardiAMP Cell Therapy System, a catheter-delivered autologous cell therapy for ischemic heart failure, clearing the way for a marketing approval application. The therapy has been studied across three clinical trials encompassing more than 200 patient procedures, including two randomized, double-blind, placebo-controlled studies. Consultation completion is a procedural milestone rather than approval, with first Japanese patient treatment and commercial revenue targeted for 2028.
Key Points
- PMDA consultations completed for catheter-based autologous cell therapy in heart failure
- Evidence base spans three trials, over 200 patient procedures
- Milestone is procedural; approval and 2028 commercialization remain pending
Longevity Analysis
Ischemic heart failure represents a failure of the heart muscle to regenerate after circulatory injury, and autologous cell therapy targets that repair deficit directly rather than managing downstream symptoms. Minimally invasive catheter delivery lowers the procedural burden that often excludes older or frailer patients from regenerative interventions, widening who can access tissue-level repair. Regulatory pathways in Japan have historically moved faster on cell-based therapies, making this jurisdiction a meaningful indicator of how quickly restorative cardiac treatments reach clinical practice.
Original published by LT Wire.